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Summary 
In steroid-resistant (SR) asthma, there is a lack of clinical responsiveness to oral prednisone. Previous 
studies indicate that this may be explained by the effect of the combination of interleukin 2 
(IL-2) and IL-4 on glucocorticoid receptor binding affinity. By contrast, steroid-sensitive  (SS) 
asthmatics respond well to glucocorticoids, and this is accompanied by a decrease in the numbers 
of bronchoalveolar lavage (BAL) messenger RNA + (mRNA +) cells expressing IL-4 and IL-5, 
and an increase in interferon "y (IFN-3~) transcripts. In the present study, we hypothesized that 
SR asthma is associated with alterations  in T  helper types 1/2 (Th2/Thl)-type cytokine gene 
expression.  BAL was performed in six SR asthmatics and six SS asthmatics, before and after 
a 1-wk course of 40 mg daily prednisone, mRNA + cells for IL-2, IL-4, IL-5, and IFN-qr was 
measured by in situ hybridization using 3sS-labeled RNA probes.  Before prednisone therapy, 
there were significantly  greater numbers of BAL cells (per 1,000) expressing IL-2 mRNA (p 
<0.01) and IL-4 mRNA (p <0.05) in SR asthmatics as compared with SS asthmatics, but no 
differences between the two groups in the numbers of BAL cells expressing IFN-3, or IL-5 mRNA 
expression were observed.  After a 1-wk course of prednisone, IL-2 expression was not altered 
in either group. However, SS asthmatics had a significant decrease in the numbers of BAL cells 
expressing mRNA for IL-4 (p <0.01) and IL-5 (p <0.001), and a rise in the numbers of IFN-v 
mRNA +  cells  (p  <0.01).  tn  contrast,  after  prednisone treatment,  SR  asthmatics  had  no 
significant  change in either the number of BAL cells expressing mRNA for IL-4 or IL-5.  Of 
note, there was an unexpected decrease in the numbers of IFN-'/mRNA + cells (p  =  0.05). 
Our current findings indicate that SR asthma is associated with a dysregulation of the expression 
of the genes encoding for Th2/Thl cytokines in airway cells and is compatible with the concept 
that a combination of IL-2 and IL-4 induce glucocorticoid (GR) binding affinity  and T  cell 
responsiveness  to glucocorticoids. 
ecent National Institutes of Health (NIH) guidelines for 
the treatment of asthma have focused on early inter- 
vention with antiinflammatory therapy, particularly inhaled 
glucocorticoids (1). However, a subset of asthmatics fails to 
demonstrate a satisfactory response even to systemic gluco- 
corticoid therapy (2, 3) and has been termed "steroid resis- 
tant" (SR) 1. It is important to recognize these patients early 
because failure to respond to steroids often leads to courses 
of very high dose glucocorticoid therapy and consequent ad- 
1 Abbreviations used in this paper: BAL, bronchoalveolor  lavage; FEVb 
forced e~piratory volume in I s; GR, glucocorticoid receptor; SR, steroid- 
resistant; SS, steroid-sensitive. 
verse effects despite persistent airway compromise (4). Indeed 
the documented rise in asthma mortality during the past de- 
cade, despite the use of glucocorticoids for asthma therapy 
in many countries, raises the question of whether a propor- 
tion of these patients were indeed SR. Since these patients 
likely evolve over time, understanding mechanisms involved 
in glucocorticoid  resistance could lead to earlier identification 
of this challenging group of asthmatics and provide insight 
for new directions in the management of severe  chronic asthma. 
The actual mechanism by which glucocorticoids reduce 
airway inflammation in asthma remains poorly understood. 
However, at least one aspect of its action likely relates to the 
modulation of cytokine production (5). In this regard, re- 
cent bronchoalveolar lavage (BAL) studies in atopic asthmatics 
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mRNA for IL-4 and IL-5 (6).  These two cytokines play a 
critical role in the induction of IgE synthesis as well as the 
recruitment, activation, and survival  of eosinophils,  a cell 
thought to play an important role in mediating inflamma- 
tion and epithelial damage in asthmatic airways (7, 8). Re- 
cent studies indicate that steroid-sensitive  (SS) asthmatics re- 
spond to prednisolone therapy with a reduction in eosinophils 
as well as a decrease in activated T cells expressing  IL-4 and 
IL-5 mKNA transcripts but an increase in IFN-'y (9). To gain 
further insight into potential mechanisms by which glucocor- 
ticoids act in vivo, it is also of interest to study patients who 
fail to respond to steroid therapy. 
Previous studies on PBMCs from patients with SR asthma 
have demonstrated that glucocorticoids fail to inhibit their 
mitogen-induced T cell proliferation and cytokine secretion 
in vitro (10, 11). In addition, T cells from peripheral blood 
of SK asthmatics, but not SS asthmatics, are persistently ac- 
tivated despite continued treatment with aggressive steroid 
therapy (12). Recently, we have found that the majority of 
patients with SR asthma have a reversible defect in glucocor- 
ticoid receptor (GR)-binding affinity  which can be sustained 
in vitro by the addition of the combination of IL-2 and IL-4 
but not the individual cytokines (13). Furthermore, in vitro 
incubation of normal T cells with the combination of IL-2 
and IL-4, in the absence of IFN-3,, reduces their GR-binding 
affinity to the level seen in SR asthma (14). These in vitro 
data suggested that the pattern of cytokine gene expression 
may play a role in determining steroid resistance. In the cur- 
rent study, we therefore used the technique of mRNA in 
situ hybridization to examine whether airway cells from SR 
asthmatics vs. SS asthmatics expressed different patterns of 
cytokines, particularly after treatment with oral steroids. 
Materials and Methods 
Patients.  12 consecutive patients with a diagnosis of asthma, 
based on The American Thoracic Society (ATS) criteria (15), who 
fulfilled the entry criteria of this study and were willing to un- 
dergo the procedures related to this protocol were studied. At base- 
line, all subjects had a morning prebronchodilator forced expira- 
tory volume in 1 s (FEV1) <70% of predicted values  and a 915% 
increase in FEV1 after two inhalations of albuterol (90 #g/actua- 
tion). None of these patients had evidence for other types of lung 
disease, pregnancy, suspected  noncompliance  with medical  care, or 
concurrent therapy with medications that alter glucocorticoid me- 
tabolism, such as anticonvulsants or erythromycin. 
Study  Design.  Informed consent, approved by the National 
Jewish Center Institutional Review Board, was obtained from all 
patients before their entry into this study. All patients entering 
into this study agreed to undergo fiberoptic bronchoscopy with 
BAL and flow spirometry, immediately before and after a 1-wk 
course of  oral prednisone taken 20 mg twice per day. Flow spirom- 
etry was carried out in accordance  with the ATS standardized  guide- 
lines (16). At each timepoint, patients had three FEV1 measure- 
ments,  and the  best of two FEV1 measurements, which  were 
within 5% of each other, was used. BAL fluid was analyzed for 
cytology, numbers of T cells expressing the HLA-DR activation 
antigen by flow cytometry, and cytokine gene expression  by in situ 
hybridization. BAL fluid was analyzed for cytology, numbers of 
T cells expressing the HLA-DR activation antigen by flow cytom- 
etry, and cytokine gene expression by in situ hybridization. 
Patients were classified  as SS or SR based on their prebronchodi- 
lator morning FEVI and response to a course of oral prednisone 
in the current  study. Compliance with prednisone therapy was 
documented  by monitoring plasma morning cortisol  levels and pred- 
nisolone levels (the active metabolite of prednisone) as indicated 
in Table 1. Asthmatic patients were defined as SR if they failed 
to improve their morning prebronchodilator FEV1 by t>15% after 
a 1-wk course of oral prednisone (13, 16). Patients were classified 
as SS if they had an increase in FEVI i>30% above baseline. 
Fiberoptic Bronckoscoi~.  Each  subject had a baseline and post- 
treatment bronchoscopy performed at the same time of day. The 
baseline bronchoscopy occurred on the day that prednisone treat- 
ment was initiated. The final bronchoscopy  was performed within 
12 h after the last dose ofprednisone. The fiberoptic  bronchoscopy 
was well tolerated  by all subjects without any significant  side effects 
during or after the procedure. 
Bronchoscopy with BAL was performed by our previously de- 
scribed method (17). Prebronchoscopy medications for each sub- 
ject included intramuscular  injections  of  60 mg codeine  and 0.6 mg 
atropine, 4% xylocaine nebulized to the nasopharynx, 5-8 nag of 
intravenously  administered  midazohm, a total of  6 ml of 1% xylo- 
caine directly applied to the laryngeal area via the bronchoscope, 
and 2 ml of 1% xylocaine directly applied to each of the trachea, 
right mainstem bronchus, and opening of the right middle lobe. 
Nasal oxygen at 4 liter/rain was used throughout the procedure. 
A different segment of the right middle lobe was lavaged at each 
bronchoscopy, using five  60-ml aliquots of 36~  sterile normal sa- 
line after the bronchoscope was wedged into a subsegment. The 
BAL fluid was harvested by immediate, gentle-hand suction ap- 
plied to each instilling syringe. 
CeUular  Analysis of  BAL Cells.  BAL fluid  analysis  was performed 
immediately  after the bronchoscopy  and was independently  verified 
by two technicians blinded to the subjects' condition. The total 
cell count was determined by using the original lavage fluid sus- 
pension, and the differential  cell  analysis  was prepared by the cytocen- 
trifuge method using the Diff-Quik  |  stain (American Scientific 
Products, McGraw Park, IL) (18). For analysis of the number of 
activated  T cells expressing the HLA-DR surface antigen, aliquots 
of 5  x  10  s BAL cells were incubated for 30 rain at 4~  with 
FITC-conjugated anti-HLA-DR and PE-conjugated anti-CD3 or 
respective IgGI-FITC and IgG2-PE isotype controls from Becton 
Dickinson & Co. (Mountain View, CA).  After two washes in 
medium, fluorescence  intensity was analyzed  with a FACScan  |  flow 
cytometer  (Becton  Dickinson  & Co.) as previously  described  (19, 20). 
In Situ Hybridization.  BAL cells suspended at a concentration 
of 105 cells/ml in RPMI 1640 (Flow Laboratories, McLean, VA) 
were cytospun at 800 rpm for 5 rain onto poly t-Lysine  coated  slides. 
Cytospins were then air-dried for 5 min, fixed  in 4% paraformalde- 
hyde in PBS (pH 7.2) for 30 min, followed  by two changes of 15% 
PBS-sucrose for 1 h each. Slides were then incubated at 37~  and 
stored at  -80~  before hybridization. 
In situ hybridization was performed as previously described (6, 
21, 22). Briefly,  3sS-UTP-labeled RNA probes were prepared from 
cDNA for IL-2, IL-4, IFN-% and IL-5. To avoid  nonspecific  binding 
of 3sS-labeled RNA probes, incubation with N-ethyl maleimide, 
iodoacetamide,  and triethanolamine  was included  in prehybridization 
steps, and dithiothreitol (150 raM) was included in the hybridiza- 
tion mixture (Sigma Chemical Co., St. Louis, MO). As a negative 
control, preparations  were hybridized  with sense  probes or pretreated 
with RNase before hybridization (Promega, Southampton, UK). 
Positive controls were prepared from a concanavalin  A-stimulated 
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Parameter  SS asthma  SR asthma 
No.  of Subjects 
Age 
Sex (M/F) 
Mean weight  (kg) 
Inhaled steroids (yes/no) 
Systemic steriods (yes/no) 
Duration of asthma (yr) 
Allergen prick skin test 
Baseline FEV1 (percent pred)* 
FEV1 after prednisone (percent pred)s 
Baseline AM cortisol (mcg/dl) 
AM cortisol after prednisone 
Baseline prednisolone levels  (ng/ml) 
Prednisolone levels after prednisone 
Percent BAL eosinophils  (baseline) 
Percent BAL eosinophils after prednisone 
Percent BAL HLA-DR + T  cells (baseline) 
Percent BAL HLA-DR + T  cells after prednisone 
6  6 
31  +3  30+2 
4/2  5/1 
73  +  7  72  -+  5 
3/3  3/3 
0/6  0/6 
23  +  2  26  +  2 
6/6 positive  6/6 positive 
47  +  3  56  +  2 
78+_2  61  .+3 
10.6  .+  4.7  15.2  +_  2.6 
011  0.2  +_ 0.211 
0  0 
131.5  .+  37.6 II  96.1  +_ 35.8 I 
16  .+  4  10  .+  2 
8_+24  11.+5 
30  .+  11  42  .+  10 
9.+  2*  50  +_  12 
* All values represent mean -+ SEM. 
Mean AM prebronchodilator FEV1 value of patients before burst. 
S Mean AM prebronchodilator FEV1 value following a 1-wk course of prednisone 20 mg orally twice daily. The SS, but not the SR, asthma group 
demonstrated a significant (p <0.01) rise in FEV1 after prednisone therapy. 
II After prednisone therapy, AM cortisol levels decreased significantly (t, <0.01) and prednisolone levels increased significantly (p <0.05) in the SS 
and SR asthma groups. Plasma cortisol and prednisolone levels were determined by a high performance liquid chromatography method described 
in reference 31. 
'1 After prednisone therapy, the percentages of eosinophil in BAL decreased significantly in SS asthma (p <0.05) as compared with SR asthma. 
** After prednisone therapy, the percentages of activated HLA-DR + T cells in BAL decreased significantly  (p <0.05) in SS asthma, but not SR asthma. 
human T cell clone known to produce IL-2, Ib4, and I1_,5, or from 
PHA-stimulated mononuclear calls for Ib2 and IFN-% 
Counting was done in a blinded fashion without knowledge 
of treatment groups or diagnosis. Hybridization between cytokine 
mKNA and cKNA probes was identified as dense collections of 
silver grains  overlying cells. Hybridization signals  were assessed 
by counting mRNA positive cells/I,000 total BAL cells on at least 
two slides for each cytokine probe and counts were performed in 
triplicate.  The intraobserver coef~cient of variation was <5%. 
Statistical Analysis.  Statistical  comparison of BAL differential 
counts, T cells expressing HLA-DR and in situ hybridization results 
was performed with the Wilcoxon Signed Rank Test within groups 
and the Wilcoxon Rank Sum Test between groups, p values g0.05 
were considered statistically  significant. 
Results 
Clinical Features and Physiologic Re~nse To Prednison~  Patient 
characteristics are summarized in Table 1. SR and SS asth- 
matics were similar for all parameters with one exception: 
although the SR asthmatics had a higher baseline FEV1 (p 
<0.05) before the prednisone course, as compared with the 
SS asthma patients,  their FEV1 after treatment  with pred- 
nisone was significantly lower than SS asthmatics (p <0.01). 
Of note, none of the patients entered in this study had re- 
ceived a course of prednisone for at least 2  mo before en- 
rollment. 
Compliance with prednisone therapy was documented by 
obtaining AM plasma cortisol levels and prednisolone levels 
before and after the course of prednisone.  AM plasma cor- 
tisol levels were similar at baseline for each group. As shown 
in Table 1, after prednisone therapy, both study groups had 
a significant decrease in morning cortisol (p <0.01)  as well 
as significant increase in plasma prednisolone levels (p <0.05). 
Analysis of  BAL Cells.  At baseline, there was no significant 
difference between total white cell counts, percentage of eoo 
sinophils, or activated T cells in BAL fluid from the SR asthma 
group versus the SS asthma group (Table 1). However, after 
prednisone  therapy, there was  a  significant  decrease in the 
percentage of BAL eosinophils ~  <0.05) as well as percentage 
of BAL-activated T  cells ~  <0.05) in the SS asthma group. 
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Figure 2.  Number of cells with positive hybridiza- 
tion signals  for IL-2  and II--4  mRNA in BAL fluid from 
six patients with SS asthma and six patients with SK 
asthma obtained before and after treatment with pred- 
nisone. Before prednisone therapy, there were signifi- 
cantly more cells expressing IL-2 (p <0.01) and II.-4 
(p < 0.05) mKNA in the BAL fluid of patients with 
SR asthma as compared with SS asthma. Values were 
compared by the Mann-Whitney U  test. 
In contrast, in the SK asthma group, prednisone therapy was 
not accompanied by any significant changes in percentage of 
BAL eosinophil counts or BAL-activated  T  cells. 
Cytokine Gene Expression in the Airways of SS vs. SR Asth- 
matics.  Positive  in situ hybridization signals for cytokine 
mKNA were observed as dense collections of silver grains 
overlying BAL cells on autoradiographs only when antisense 
probes were used. No signals were observed on cytospins hy- 
bridized with sense probes, nor from preparations pretreated 
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Figure 3.  Number of cells with positive hybridization signals for II--5 
mRNA in BAL fluid from six patients with SS asthma and six patients 
with SR asthma obtained before and after treatment with prednisone. Be- 
fore prednisone therapy, there were no significant difference in numbers 
of Ib5 mRNA-expressing cells (p  =  0.7) in the BAL fluid of patients 
with SR asthma as compared with SS asthma. After prednisone therapy 
SS asthma, but not SR asthma, was associated with a significant decrease 
in numbers of Ib5 mRNA(+) cells (p <0.001). 
showing signals from BAL cells of SS asthmatics or SR asth- 
matics hybridized with antisense riboprobes to IL-4 and IL-5 
are shown in Fig. 1. A variable number of positive hybridiza- 
tion signals were observed for each cytokine in the SS vs. 
SR asthma groups depending on whether the sample was 
obtained before or after prednisone therapy. 
As shown in Fig. 2, before prednisone therapy, BAL cells 
from patients with SR asthma, as compared with cells from 
SS asthma, had a significantly higher number of ceUs expressing 
positive hybridization signals for IL-2 mRNA (p <0.01) and 
IL-4 mRNA (p <0.05). However, no significant differences 
between these two patient populations were observed in the 
iFN-y mRNA (+) [ 
cells per 1000 |  Steroid Sensitive  Steroid Resistant 
1 5  I-  P<0.01-7  [--P=O.05 -'1 
O" 
B~om  After  Before  After 
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Figure 4.  Number of ceils with positive hybridization signals for IFN-3' 
mRNA in BAL fluid from six patients with SS asthma and six patients 
with SR asthma obtained before and after treatment with prednisone. After 
prednisone  therapy,  there  was  a  significant  rise  (p  <0.01)  in IFN-3' 
mRNA +  cells in  SS  asthma,  but  a  decrease in  numbers of IFN-3, 
mRNA + cells (p  =  0.05) in SR asthma. 
Figure  1.  Autoradiographs  of cytospin preparations of BAL cells from a StL asthmatic hybridized with an antisense riboprobe  to Ib4 before (A) 
and after (B) prednisone therapy; a SR asthmatic  hybridized with an antisense riboprobe to II.-5 before (C) and after (D) prednisone therapy; a SS 
asthmatic hybridized with an antisense riboprobe to IL-5 before (E) and after (F) prednisone therapy; a SS asthmatic hybridized with IFN-~/antisense 
probe after prednisone therapy (G); a representative control example of a BAL preparation from a SR asthmatic tested with a sense IL-4 probe (H). 
The positive hybridization  signals are the dense collections of silver grains overlying BAL cells. 
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(Fig. 4). After prednisone therapy, BAL cells from SS asth- 
matics demonstrated a significant decrease in the number of 
cells expressing IL-4  mRNA  ~  <0.01,  Fig.  2)  and IL-5 
mRNA  (p <0.001,  Fig.  3).  In contrast,  after  prednisone 
therapy,  BAL fluid from patients with SR asthma did not 
demonstrate any significant alteration in the number of BAL 
cells expressing either IL-4 mRNA or IL-5 mRNA. Fur- 
thermore, although small reductions in the numbers of BAL 
cells/I,000 positive for IL-2 mRNA accompanied prednisone 
therapy in each patient group, these differences were not 
significant  (Fig.  2). 
As shown in Fig. 4, treatment of SS asthmatics with pred- 
nisone resulted in a significant  rise in the numbers of BAL 
cells expressing  mRNA for IFN-y (p <0.01).  In contrast, 
when SR asthmatics were treated with prednisone, their BAL 
cells demonstrated a  decrease  in  the  numbers of IFN-y 
mRNA + cells (p =  0.05). These divergent responses resulted 
in a highly significant  difference in IFN-y gene expression 
after prednisone treatment between the SS vs. SR asthmatic 
groups (p <0.01). 
Discussion 
This is the first study demonstrating that the BAL cells 
from the airways of patients with SR. asthma have a distinct 
pattern of cytokine gene expression, and response to predni- 
sone which differs from that found in SS asthma. Of note 
we found that, both before and after prednisone therapy, BAL 
cells from SR asthmatics had a significantly  higher level of 
IL-2 and IL-4 gene expression than BAL cells from SS asth- 
matics. This is of particular interest because previous in vitro 
studies have demonstrated that the combination of IL-2 and 
IL-4 is required to reduce the GR-binding affinity in normal 
peripheral blood T cells (13). Furthermore, T cells from the 
majority of patients with SR asthma have a GR binding de- 
fect which reverses in culture. Although, this defect is sus- 
tained in vitro by the presence of the combination of IL-2 
and IL-4, incubation with IL-2 or IL-4 alone is not sufficient 
to mediate an effect on GR binding affinity  (12). 
The method of in situ hybridization is semiquantitative 
and it is possible that mRNA expression may not always lead 
to cytokine production. Analyses of cytokine protein in con- 
centrated BAL fluid from atopic asthmatics have, however, 
revealed a pattern similar to that detected at the level ofmRNA 
(23).  Therefore, it is most likely that our current data on 
cytokine mRNA expression reflects cytokine production in 
the airways of SS vs. SR asthmatics. 
We have previously reported that IL-5 has no effect on GR 
binding affinity  (12). However, T  cells are a major source 
of IL-5 in asthmatic airways. Therefore, the failure ofpredni- 
sone to inhibit airway T cell activation in SR asthma (Table 
1) as well as peripheral blood T cell activation (see references 
9 and 10), may have important pathologic consequences in 
that IL-5 gene activation will be sustained and therefore con- 
tinue to promote eosinophil differentiation and survival in 
the airways of SR asthmatics.  Indeed, our current findings 
provide an immunologic basis for the original description 
by Schwartz et al. (2), in 1968, of SR asthma where he noted 
that prednisone did not suppress peripheral eosinophil counts 
in these patients. 
An interesting finding in this study was the observed de- 
crease in the number of BAL cells expressing IFN-y mRNA 
in SR asthmatics after treatment with prednisone. A previous 
study in SS asthmatics demonstrated that improvement in 
pulmonary function after prednisolone treatment was accom- 
panied by a significant  increase in the number of cells ex- 
pressing mRNA for IFN-"/(9). Our current study confirms 
this observation in that we also found an increased number 
of BAL cells expressing IFN-7 mRNA in SS asthmatics after 
prednisone therapy as compared with baseline values (Fig. 
4). These data suggest that IFN-'), producing type 1 T helper 
(Thl)-like cells, as compared with IL-4 or IL-5 secreting type 
2 T helper (Th2)-like cells, may be more sensitive to the in- 
hibitory effects of glucocorticoids. Although a previous study 
(6) of patients with chronic allergic asthma demonstrated that 
IL-4 and IL-5 expression were primarily localized to T cells, 
recent reports indicate that other cells can also express these 
cytokines to varying degrees (24, 25). Future studies are there- 
fore needed to determine the cell source of these various 
cytokines in SR asthma, and their relative sensitivity to the 
effects of glucocorticoids. 
The precise mechanisms by which different  patterns of 
cytokines or immune activation might result in decreased ste- 
roid responsiveness in asthma remain to be elucidated.  We 
have previously reported that PBMCs from the majority of 
patients with SR asthma have reduced GR binding affinity 
and have postulated that these may contribute to decreased 
responses to corticosteroids (13). Furthermore, we found a 
marked difference between the nuclear and cytosolic  GR- 
binding parameters of peripheral blood T  cells from SR 
asthma. In this regard, it is well known that the GR changes 
its structure and/or conformation when translocated between 
the cytosol and nucleus (reviewed in reference 26). The acti- 
vated GR nuclear complex regulates transcription by binding 
to specific DNA sequences, called glucocorticoid-responsive 
elements.  The induction or repression  of GR target genes 
ultimately results in the altered expression of glucocorticoid- 
regulated proteins (27). This latter action appears to be medi- 
ated via direct binding of the modulatory domain of the GR 
with transcriptional factors, such as AP-1. However, overex- 
pression of AP-1 or other transcription factors has been found 
to interfere with GR function (28). Since our current studies 
demonstrate that SR asthma is associated with much higher 
levels of cytokine activation than SS asthma (Fig. 2), the acti- 
vation of particular transcription factors such as AP-1 (29) 
may provide a plausible explanation for the nuclear localiza- 
tion of the GR-binding defect in SR asthma and differences 
in patterns of steroid  responsiveness in asthma. 
Our study also raises the intriguing possibility that SR 
asthma may be the end result of ongoing immune activa- 
tion. It has been previously demonstrated that PHA-induced 
T cell proliferation and cytokine production by PBMC from 
patients with SR asthma is poorly inhibited by the addition 
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cently, we reported several SR patients whose asthma came 
under control with the combination of troleandomycin and 
methylprednisolone therapy and this resulted in normaliza- 
tion of T cell sensitivity in vitro to the inhibitory effects of 
methylprednisolone on T lymphocyte proliferation (11). Fur- 
thermore, cyclosporin A, a drug whose major action is inhi- 
bition  of T  cell proliferation  and  cytokine secretion,  was 
reported to improve the clinical symptoms of several patients 
with SR asthma (30). These observations are consistent with 
the notion that ongoing asthma inflammation and cytokine 
secretion may contribute to the acquired GK defect found 
in SR asthma. 
In conclusion, our current findings may have several im- 
portant implications toward understanding  the pathophysi- 
ology of chronic asthma.  First,  with the increasing use of 
corticosteroids in the treatment  of asthma,  it is important 
to recognize that  such patients may vary in their response 
to steroids. Second, the observation of a distinctive pattern 
of cytokine gene expression in SR asthma is consistent with 
the possibility that different patterns of cytokine expression 
alter response to therapy. While many of these patients may 
respond to an extremely high dose of glucocorticoids such 
treatment carries the risk of serious side effects.  Continued 
research is needed to define the mechanisms of action for on- 
going airway immune activation, correlation of response to 
particular treatment strategies and thereby identify the most 
appropriate  treatment  regimen for a particular  pathway of 
cellular activation. An understanding of the mechanisms by 
which glucocorticoids fail to resolve inflammation in asthma 
may provide important  insight  into its pathogenesis,  espe- 
cially as related to progressive pulmonary deterioration. This 
new information may then trigger new approaches for the 
management  of this challenging  respiratory condition. 
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